In a new letter, researchers from Wuhan Children’s Hospital in Wuhan, China, have provided insights on early-onset SARS-CoV-2 infection in neonates
In a new letter, researchers from Wuhan Children’s Hospital in Wuhan, China, have provided insights on early-onset SARS-CoV-2 infection in neonates. The report appears in JAMA Pediatrics.
In their hospital, the authors treated 33 neonates born to mothers with COVID-19. Their account describes outcomes in three of the neonates who also were diagnosed with the virus. Data included were collected from January 2020 to February 2020.
Cases
Born at 40 weeks’ gestation to a mother with COVID-19 pneumonia, the infant in Case 1 was lethargic and had a fever on Day 2 of life. Chest x-ray showed pneumonia but all lab tests other than for procalcitonin were normal. Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on Days 2 and 4 but negative on Day 6.
Also born to a mother with confirmed COVID-19 pneumonia, the infant in Case 2 had lethargy, vomiting and fever. Chest x-ray showed pneumonia and lab tests showed leukocytosis, lymphocytopenia, and an elevated creatine kinase-MB fraction. As with the infant in Case 1, nasopharyngeal and anal swabs were positive for SARS-CoV-2 on Days 2 and 4 but negative on Day 6.
The infant in Case 3 required resuscitation after cesarean at 31 weeks, 2 days for fetal distress and maternal COVID-19 pneumonia. He was treated with noninvasive ventilation, caffeine, and antibiotics for neonatal respiratory distress syndrome and pneumonia, which resolved on Day 14 of life. Antibiotics also were administered for suspected sepsis. On Days 2 and 4, nasopharyngeal and anal swabs were positive for SARS-CoVo-2 and negative on Day 7.
Symptoms
The authors described symptoms in all 33 infants-including the three infected neonates-as “mild” and their outcomes as “favorable.” They speculated of the most seriously ill neonate that he “may have been symptomatic from prematurity, asphyxia, and sepsis, rather than SARS-CoV-2 infection.”
Conclusions
The researchers concluded that “it is crucial to screen pregnant women and implement strict infection control measures, quarantine of infected mothers, and close monitoring of neonates at risk of COVID-19.”
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More